Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 1
Submit an article Journal homepage
768
Views
7
CrossRef citations to date
0
Altmetric
Author's View

SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer

Abhishek K. SrivastavaInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MDUSA
,
Esma S. YolcuInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA
,
Gunes DincInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Ahi Evran University, School of Medicine, Department of Medical Biyology, Kirsehir, Turkey
,
Rajesh K. SharmaInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA
&
Haval ShirwanInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA;James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USACorrespondence[email protected]
Article: e1064580 | Received 15 Jun 2015, Accepted 16 Jun 2015, Published online: 25 Jan 2016

References

  • Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H, Shirwan H. SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res 2014; 74:6441-51; PMID:25252915; http://dx.doi.org/10.1158/0008-5472.CAN-14-1768-A
  • Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-gamma. PLoS One 2012; 7:e42459; PMID:22870329; http://dx.doi.org/10.1371/journal.pone.0042459
  • Sharma RK, Schabowsky RH, Srivastava A, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, et al. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 2010; 70:3945–54; PMID:20406989; http://dx.doi.org/10.1158/0008-5472.CAN-09-4480
  • Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel from of 4-1BBL eradicates established tumors. Cancer Res 2009; 69:4319–26; PMID:19435920; http://dx.doi.org/10.1158/0008-5472.CAN-08-3141
  • Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007; 179:7295–304; PMID:18025172; http://dx.doi.org/10.4049/jimmunol.179.11.7295
  • Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines 2014; 13:387–98; PMID:24521311; http://dx.doi.org/10.1586/14760584.2014.880340
  • Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623–33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947
  • Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007; 8:1002–8; PMID:18058571
  • Sharma RK, Yolcu ES, Srivastava AK, Shirwan H. CD4(+) T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One 2013; 8:e73145; PMID:24066030; http://dx.doi.org/10.1371/journal.pone.0073145
  • Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G, Shirwan H. Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8+ T and NK cell dependent manner. PLoS One 2012; 7:e48463; PMID:23144888; http://dx.doi.org/10.1371/journal.pone.0048463

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.